Navigation Links
Acidic tumor pH inhibits drug effect
Date:2/11/2014

Low pH in tumours counteracts the desired effect of the drug chloroquine, according to a new study from Karolinska Institutet in Sweden. The results, which are published in the journal Autophagy, might explain possible lack of efficacy of chloroquine in clinical studies.

Chloroquine, a widely used antimalaria drug, is currently under investigation in clinical trials on cancer patients. It is the ability of chloroquine to inhibit autophagy in tumour cells that has piqued researchers' interest. Autophagy is a homeostatic process by which cells eat parts of themselves, so that damaged or unnecessary organelles and toxic proteins are broken down and recycled. In the absence of nutrients, cells resort to autophagy to survive. This way, autophagy helps cancer cells survive in tumour regions that are poor in nutrients and characterised by low oxygen and acidic pH.

Also, tumour cells use autophagy to protect themselves from many forms of anticancer therapies, including chemotherapy. Several studies have shown that inhibition of autophagy often increases chemosensitivity and radiosensitivity in tumour cells. Chloroquine combined with existing cancer treatment is thus considered to be a promising strategy. However, in some cancer models chloroquine seems to be unable to block autophagy, but the underlying mechanisms have not yet been identified.

In the present study, the scientists studied the effect of chloroquine in different cancer cells that were either cultured in acidic pH for a short time or adapted to chronic acidosis. The researchers also studied the effect in tumours grown in mice.

We discovered that a major consequence of the altered metabolism of tumour cells, the tissue acidification, is responsible for the lack of chloroquine anti-autophagic activity. The results suggest that chloroquine might lack efficacy in patients whose tumours are characterised by acidic regions, says Angelo De Milito at the Department of Oncology-Pathology at Karolinska Institutet, principal investigator of the study.

In the context of cancer therapy, the finding may be of importance for the translation of preclinical findings to the clinical setting in patients. The research was funded by Association for International Cancer Research, the Swedish Cancer Society, and the Sigurd and Elsa Goljes Foundation.


'/>"/>

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert  

Related biology news :

1. Corals could survive a more acidic ocean
2. Cystic fibrosis makes airways more acidic, reduces bacterial killing
3. Glimpse into the future of acidic oceans shows ecosystems transformed
4. New studies needed to predict how marine organisms may adapt to the futures acidic oceans
5. The loss of a protein makes jump the tumor to the lymph node
6. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
7. Dental X-rays linked to common brain tumor
8. TGen leads new National Institutes of Health study of brain tumors
9. Immune-response genes affecting breast tumor eradication
10. A single stem cell mutation triggers fibroid tumors
11. Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Acidic tumor pH inhibits drug effect
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
(Date:12/15/2016)... -- ... Research and Markets has announced the addition of the "Global Military ... report forecasts the global military biometrics market to grow at a CAGR ... been prepared based on an in-depth market analysis with inputs from industry ... the coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
(Date:1/19/2017)... ... 2017 , ... FireflySci Inc. is a go-getter type of company that continues ... to two main factors. The first is the amazing customer service that the ... products all around the world. , 2016 was a tremendous sales year for FFS ...
(Date:1/19/2017)... -- Acupath Laboratories, Inc., a leading provider of sub-specialized ... Committee that will guide the company,s vision and strategy ... , a 15-year veteran of the anatomic pathology industry, ... Chief Sales Officer .  Prior to joining Acupath ... leadership roles at several leading lab industry organizations including, ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
Breaking Biology Technology: